Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells

27 Jun 2019

Abstract excerpt

PURPOSE: The cyclin-dependent kinases (CDKs) CDK4 and CDK6 are important regulators of the cell cycle and represent promising targets in cancer treatment. We aimed to investigate the relevance of CDK4/6 in the development of hepatocellular carcinoma (HCC) and the potential of ribociclib, a novel orally available CDK4/6 inhibitor, as a treatment for HCC. METHODS: The effect of ribociclib was assessed in native and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer Mechanisms and Therapy
Share to Cancer-related Molecular Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31250364
DOI: 10.1007/s13402-019-00458-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cellsPMID 31250364Read ↗

Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivoSemantic proximity Read ↗

Molecular Pathways: Targeting the Cyclin D–CDK4/6 Axis for Cancer TreatmentSemantic proximity Read ↗

Targeting WEE1 by adavosertib inhibits the malignant phenotypes of hepatocellular carcinoma.Semantic proximity Read ↗

Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian CancerSemantic proximity Read ↗

Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma.Semantic proximity Read ↗

CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinomaSemantic proximity Read ↗

Biallelic loss of RB1 in hepatocellular carcinoma as synthetic lethal target for artificial intelligence-guided therapy.Semantic proximity Read ↗

Targeting CDK4/6 in patients with cancerSemantic proximity Read ↗

CDK4/6 inhibitor-induced liver injury: Clinical phenotypes and role of corticosteroid treatmentSemantic proximity Read ↗

The Cyclin-Dependent Kinase Inhibitor Seliciclib (R-roscovitine; CYC202) Decreases the Expression of Mitotic Control Genes and Prevents Entry into MitosisSemantic proximity Read ↗

Effect of Lenvatinib treatment on the cell cycle and microRNA profile in hepatocellular carcinoma cellsSemantic proximity Read ↗

KLF6 transcription factor protects hepatocellular carcinoma-derived cells from apoptosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.